



Bruce Walker is the Director of the Ragon Institute of MGH, MIT and Harvard, a Professor of Medicine at Harvard Medical School, a Professor of Practice at MIT and a Howard Hughes Medical Institute Investigator. In addition to his clinical duties as a board certified Infectious Disease specialist, his research focuses on cellular immune responses in chronic viral infections, with a particular focus on HIV. He leads an international translational clinical and basic science research effort to understand how some rare people who are infected with HIV, but have never been treated, can fight the virus with their immune system. Dr. Walker is also an Adjunct Professor at the Nelson Mandela School of Medicine in Durban, South Africa. There he collaborates with the Doris Duke Medical Research Institute at the University of KwaZulu-Natal and serves as a Principal Investigator in the HIV Pathogenesis

Program, an initiative to study the evolution of the HIV and the immune responses effective in controlling this virus, as well as to contribute to training African scientists. He is a member of the Steering Committee for the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), a 10-year initiative funded by HHMI to build a state of the art TB-HIV research facility at the heart of these dual epidemics in South Africa. Dr. Walker is also a member of the American Academy of Arts and Sciences, American Society for Clinical Investigation (ASCI), the American Association of Physicians (AAP), and the Institute of Medicine (IOM) of the National Academy of Sciences.



Catherine Blish, MD, PhD is an Assistant Professor of Medicine and Immunology at the Stanford University School of Medicine and an Assistant Director of the Stanford Medical Scientist Training Program (MSTP). After receiving a BS in Biochemistry with Highest Honors from the University of California, Davis, she matriculated in the MSTP at the University Of Washington School Of Medicine, receiving her MD and a PhD in Immunology. She completed residency in Internal Medicine and pursued a fellowship in Infectious Disease at the University of Washington, with a research focus on immune correlates of HIV-1 infection. Her current research aims to understand the successes and failures of the immune system in order to better harness it to prevent infections. Her lab is perhaps best known for redefining our understanding of the diversity of human natural killer (NK)

cells, a critical first line of defense against viruses and tumors. Dr. Blish has received numerous awards for research and mentoring, including the Stanford Immunology Outstanding Faculty Mentor Award, the ICAAC Young Investigator Award from the American Society for Microbiology, the Beckman Young Investigator Award, the McCormick Faculty Award, the Baxter Faculty Scholar, the Doris Duke Charitable Foundation Clinical Scientist Development Award, the Tashia and John Morgridge Faculty Scholar in Pediatric Translational Medicine, the NIH Director's New Innovator Award, was named a Chan-Zuckerberg Biohub Investigator, and was elected a member of the American Society for Clinical Investigation.



Victor Nizet is a Professor and Vice Chair for Basic Research and Chief of the Division of Host-Microbe Systems & Therapeutics at the University of California, San Diego (UCSD), School of Medicine as well as Professor at UCSD Skaggs School of Pharmacy & Pharmaceutical Sciences. Dr. Nizet received his medical training at Stanford University School of Medicine, completed a Residency and Chief Residency in Pediatrics at Harvard University's Children's Hospital in Boston, Massachusetts, and a Fellowship in Pediatric Infectious Diseases at the University of Washington's Children's Hospital in Seattle. Dr. Nizet leads a large basic and translational research laboratory focused on discovering virulence factors of Gram-positive bacterial pathogens, elucidating mechanisms of host innate

immunity, and novel approaches to infectious disease therapy, and has authored 365 peer-reviewed papers. Currently, he is leading the initiative for the UCSD Collaborative to Halt Antibiotic-Resistant Microbes (CHARM) which will debut in 2017. Dr. Nizet's work has been recognized by an American Heart Association Established Investigator Award, the American Lung Association Career Investigator Award, the American Asthma Foundation Senior Investigator Award, the E. Mead Johnson Award for Research in Pediatrics, and the 2016-17 UCSD Chancellor's Associates Award for Faculty Excellence in Research in Science and Engineering. Dr. Nizet has been elected to the American Society for Clinical Investigation, the Association of American Physicians, and the American Academy of Microbiology. Details of his research program can be found at: <http://nizetlab.ucsd.edu>.



Michael Glickman holds a BA in English Literature from Dartmouth College and an MD from Columbia University College of Physicians and Surgeons. He trained in Internal Medicine at the Mass General Hospital and in Infectious Diseases at the Albert Einstein College of Medicine/Montefiore combined program. After laboratory postdoctoral training in the laboratory of William Jacobs, he assumed his independent faculty position at Memorial Sloan Kettering Cancer Center in 2001. He is now an attending physician on the Infectious

Diseases service of Memorial Hospital and a Member in the Immunology Program of the Sloan Kettering Institute. He is an incumbent of the Alfred Sloan Chair at MSKCC and Professor of Immunology and Microbial Pathogenesis, Medicine, and Molecular Biology at Weill Cornell Medicine. The Glickman laboratory has elucidated multiple virulence determinants of *M. tuberculosis*, including the Rip1 pathway of Intramembrane Proteolysis, cyclopropane modification of mycolic acids, and the CarD RNA polymerase binding protein. Other areas of interest include understanding both innate and adaptive immune recognition of *M. tuberculosis* and DNA repair pathways of mycobacteria. Finally, Dr. Glickman is co-PI (with Carl Nathan at Weill-Cornell) of the Tri-I TBRU, a collaborative translational TB research collaboration that includes the GHESKIO center in Haiti and seeks to understand latency and persistence of *M. tuberculosis*.



Ramnik Xavier, an institute member of the Broad Institute, is also Chief of Gastroenterology at Massachusetts General Hospital (MGH), Kurt Isselbacher Professor of Medicine at Harvard Medical School, and the Co-director of Center for Microbiome informatics and therapeutics, MIT. As a clinical gastroenterologist and molecular biologist, he studies the specific molecular mechanisms involved in innate and adaptive immunity as well as the genetic variants associated with Crohn's disease, ulcerative colitis, and autoimmunity. His laboratory uses genetic, structural, computational, and animal models, as well as clinical research to define the mechanisms controlling inflammation and immunity in vivo.



Oren Rosenberg is an Assistant Professor of Medicine at University of California, San Francisco and an investigator at the Chan-Zuckerberg Biohub. He was an undergraduate at Vassar College and worked in Tanzania and Guatemala with the CDC as a Watson Fellow. This experience initiated his lifelong interest in public health and infectious diseases. He was an MSTP student at Yale and then went on to complete internship and residency at Brigham and Women's Hospital. He was a clinical fellow in Infectious Diseases at UCSF and then a postdoc in the laboratories of Jeffrey Cox and Bob Stroud. His independent group, started in 2015, is using a multidisciplinary approach that combines structural biology and bacterial genetics to examine mechanisms used by intracellular bacteria to evade and exploit the host response to infection.



Andrea Cox is currently a Professor of Medicine and Oncology at The Johns Hopkins University School of Medicine in Baltimore, MD. She earned her Ph.D. studying T cell immunology at The University of Virginia. She subsequently completed an M.D. and then Internal Medicine and Infectious Disease training at Johns Hopkins. Clinically, she specializes in the treatment of patients with hepatitis virus infections and HIV. Her laboratory investigates human immune responses to HCV, HBV, and HIV, including mechanisms through which these chronic viral infections stimulate and evade immune responses, and in HCV vaccine development. She has been an active participant in clinical trials of direct-acting antivirals for the treatment of hepatitis C virus and is a principal investigator on the first prophylactic HCV vaccine trial ever implemented in an at-risk population. She has directed the Johns Hopkins Medical Scientist Training Program since 2013.



Liise-anne Pirofski is chief of the division of infectious diseases at Montefiore Medical Center and Albert Einstein College of Medicine. She received her BA from the University of California and her MD from Albert Einstein College of Medicine. She trained in Internal Medicine at Bellevue Hospital and NYU Medical Center and in Infectious Diseases at Albert Einstein College of Medicine and Montefiore Medical Center after which she did post-doctoral training at Einstein. Her research programs, which are focused on immunity to encapsulated microbes, have advanced understanding of antibody immunity and pneumococcal and cryptococcal pathogenesis. She is an editor of *mBio* and *Infection and Immunity*, and has served on numerous advisory committees, task forces, and NIH study sections, including as chair, and was IDSA chair of the inaugural IDWeek meeting. She is a member of the American Association of Physicians (AAP) and the American Academy of Microbiology (AAM), and a fellow of the American College of Physicians (FACP), the Infectious Diseases Society of America (FIDSA), and the American Association for the

Advancement of Science (AAAS). In addition to her roles as a physician-scientist and division chief, Dr. Pirofski is deeply devoted to biomedical education, mentoring and teaching. She has received the American Society for Microbiology William Hinton Mentoring Award, the Albert Einstein College of Medicine Faculty Mentoring Award, and the Harry Eagle Award for Outstanding Basic Science Teaching at Einstein. She will receive a Lifetime Achievement Award from the Einstein Alumni Association in May 2017.



Peter Hunt is an Associate Professor of Medicine and Interim Chief of the Division of Experimental Medicine at the University of California San Francisco. His primary research focus is on the inflammatory consequences of HIV infection. His translational research program seeks to understand both the causes and consequences of persistent immune activation both in the presence and the absence of antiretroviral therapy. He collaborates extensively with a multi-disciplinary team of investigators to assess the impact of persistent immune activation on mortality and chronic diseases associated with aging as well as on the persistence of HIV in cellular reservoirs. He also

conducts pilot clinical trials of novel immune-based interventions designed to decrease immune activation and recently completed a term as Chair of the Inflammation Committee of the AIDS Clinical Trials Group. Dr. Hunt has also led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting and has helped develop a large mucosal immunology program at San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection. In July, 2016, he also started a laboratory to identify the determinants of persistent adaptive immune defects in treated HIV infection, which likely contribute to infectious and neoplastic complications and may also serve as barriers to HIV cure.



Don Ganem is Global Head of Infectious Disease Research and VP of the Novartis Institutes for Biomedical Research. Prior to joining Novartis, Dr. Ganem was for over 25 years a Professor of Microbiology/Immunology and Medicine at the University of California, San Francisco, where he was also an Investigator of the Howard Hughes Medical Institute. His research focuses on the replication and pathogenesis of human viral pathogens, including hepatitis B virus and human herpesvirus 8, the causative agent of Kaposi's sarcoma. His clinical interests include chronic viral infections, infections of the immunocompromised host and hospital-acquired infections with multi-resistant bacterial pathogens. Dr. Ganem is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Academy of Microbiology. He is also a past President of the American Society for Virology. He received his B.A. and M.D. degrees from Harvard University, and underwent postgraduate clinical and scientific training at the Brigham and Women's Hospital and UCSF.



Martin S. Hirsch, M.D. is Professor of Medicine at the Harvard Medical School, Professor of Infectious Diseases and Immunology at the Harvard School of Public Health, and a senior physician in the Infectious Diseases Service at the Massachusetts General Hospital. He is also the Editor in Chief of the Journal of Infectious Diseases. For over 40 years, Dr. Hirsch has worked in virology research. He has also trained many of the current leaders in virology and AIDS research. His group was the first to show that HIV could be isolated from both male and female genital secretions, as well as from the central nervous system. His laboratory conducted the first studies of antiretroviral drug combinations in

vitro, and he has extended these efforts into clinical trials of antiretroviral combination strategies that have helped revolutionize therapy for HIV-infected individuals. Dr. Hirsch serves on the International Antiviral Society-USA (IAS-USA) Panel on Antiretroviral Therapy, as well as the Department of Health and Human Services (DHHS) Panel of Antiretroviral Guidelines for Adults and Adolescents, and chairs the NIH HIV Vaccine Data Safety Monitoring Board. He formerly was Chair of the Harvard AIDS Clinical Trials Group (ACTG), as well as Chair of the Executive Committee of the national ACTG program. Dr. Hirsch has won numerous awards, including Maxwell Finland Award for Lifetime Scientific Achievement from the National Foundation for Infectious Diseases (NFID), the Lifetime of Leadership Award from the IAS-USA, and the Mentor Award from the Infectious Diseases Society of America (IDSA).